- COMPOUNDS AND USES THEREOF
-
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
- -
-
Paragraph 1315; 1324
(2019/11/11)
-
- Compound as potassium channel modulator
-
The invention relates to a compound as a potassium channel modulator, which is a compound of a formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof is effective for curing and preventing diseases and symptoms influenced by the activity of potassium ion channels.
- -
-
Paragraph 0575; 1146; 1148; 1151; 1152
(2018/07/30)
-
- Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents
-
Epilepsy is a kind of disease with complicated pathogenesis. KCNQ (Kv7) is a voltage dependent potassium channel that is mostly associated with epilepsy and thus becomes an important target in the treatment of epilepsy. In this paper, a series of substituted piperidine derivatives targeting KCNQ were designed and synthesized by using scaffold hopping and active substructure hybridization. Compounds were evaluated by fluorescence-based thallium influx assay, Rb+ flow assay and electrophysiological patch-clamp assay. Results showed that some compounds possessed more potent potassium channel opening activity than Retigabine. More significantly, compound 11 was found to have good pharmacokinetic profiles in vivo.
- Yang, Shaoning,Lu, Dingqiang,Ouyang, Pingkai
-
p. 1731 - 1735
(2018/05/04)
-
- Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities
-
A new series of thiazole-substituted 1,1,1,3,3,3-hexafluoro-2-propanols were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Key analogs caused dose-dependent decreases in food intake and body weight in obese mice. Acute treatment with these compounds also led to a drop in elevated blood glucose in a murine model of type II diabetes.
- Tang, Haifeng,Yan, Yan,Feng, Zhe,De Jesus, Reynalda K.,Yang, Lihu,Levorse, Dorothy A.,Owens, Karen A.,Akiyama, Taro E.,Bergeron, Raynald,Castriota, Gino A.,Doebber, Thomas W.,Ellsworth, Kenneth P.,Lassman, Michael E.,Li, Cai,Wu, Margaret S.,Zhang, Bei B.,Chapman, Kevin T.,Mills, Sander G.,Berger, Joel P.,Pasternak, Alexander
-
scheme or table
p. 6088 - 6092
(2010/11/18)
-
- Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists
-
This report describes replacement of the 4-(4-fluorophenyl)piperidine moiety in our CCR2 antagonists with 4-heteroaryl piperidine and 4-(carboxyphenyl)-piperidine subunits. Some of the resulting analogs retained potency in our CCR2 binding assay and had i
- Pasternak, Alexander,Goble, Stephen D.,Vicario, Pasquale P.,Di Salvo, Jerry,Ayala, Julia M.,Struthers, Mary,DeMartino, Julie A.,Mills, Sander G.,Yang, Lihu
-
p. 994 - 998
(2008/09/19)
-